Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sonnet BioTherapeutics Holdings (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, has announced its participation in the Virtual Investor Closing Bell Series on September 9, 2024, at 4:00 PM ET. The event will feature:
- A corporate overview and business outlook by CEO Pankaj Mohan
- A moderated discussion with live Q&A opportunities
- Pre-submission of questions via email to sonn@jtcir.com
The live video webcast will be available on the company's website, with a replay accessible for 90 days following the event. This presentation offers investors a chance to gain insights into Sonnet's latest developments and future plans in the field of immunotherapy.
Details
News Market Reaction – SONN
The recorded move for SONN in the trading session of this news was +10.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live video webcast on Monday, September 9th at 4:00 PM ET
PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it will participate in the Virtual Investor Closing Bell Series on Monday, September 9, 2024, at 4:00 PM ET.
As part of the event, Pankaj Mohan, Founder and Chief Executive Officer of Sonnet BioTherapeutics, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event by emailing sonn@jtcir.com. Time permitting, the Company will respond to submitted questions.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.sonnetbio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
833-475-8247
SONN@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.